We are a cannabis cultivation and processing company positioned advantageously to address the unmet market demands and stigmas within the legal cannabis industry, with potent products designed to disturb the status quo and dramatically shift the conversation from waiting and want...
YoY sales dropped 17.4% for STIGMA GROW, signaling challenges in the <250K tier. Yet, a recent 9.3% sales increase over the last three months indicates a potential turnaround in their pricing strategy.
Categories
OralConcentratesPre-RollsFlowerVapesEdibles
Top Category: Oral
Price Tier: Mid-Market
States Active: 2
2Y Sales Trend
33.3%
Oral remains dominant at 59.2% but is down 13.4% YoY. Meanwhile, Edibles are surging at +28.1% YoY, highlighting a significant shift in consumer preferences.
Category
Sales Share
Avg Price
YoY
Oral
46.1%
$19.59
21.3%
Concentrates
28.0%
$22.86
13.5%
Pre-Rolls
15.5%
$32.97
12.2%
Flower
6.3%
$32.12
13.0%
Vapes
2.5%
$50.89
22.2%
Edibles
1.5%
$36.99
27.9%
Trend View
Market Insights SnapshotJun 2026
24-Month Trend
Average Price
$23.14
YoY Sales Trend
13.0%
2Y Sales Trend
33.3%
Category Breakout
Category
Sales Share
Avg Price
YoY
Oral
46.1%
$19.59
21.3%
Concentrates
28.0%
$22.86
13.5%
Pre-Rolls
15.5%
$32.97
12.2%
Flower
6.3%
$32.12
13.0%
Vapes
2.5%
State Rank Table
State
Oral
Concentrates
Pre-Roll
Flower
Vapes
Edibles
Alberta
4
14
⊖
⊖
⊖
⊖
British Columbia
12
25
⊖
⊖
⊖
⊖
STIGMA GROW excels in Alberta (75%) and British Columbia (25%), showcasing a concentrated geographic footprint across 2 states.
Stigma Grow Top StatesJun 2026
